Sedia Biosciences Corp.’s Post

During #WorldHealthWorkerWeek, we celebrate #SafeSupportedHealthWorkers, the backbone of resilient health systems. We recognize the critical role of health workers and are proud that Sedia Biosciences products, including Rapid Recency, can support them by providing essential information for HIV prevention and a better understanding of where new infections are occurring in real time. Together, let's honor and support these unsung heroes who are making a difference every day. #WHWWeek Frontline Health Workers Coalition

Health inequities disproportionately affect Black people and other historically marginalized groups, hindering their access to HIV prevention, treatment and care services. The National Institute of Allergy and Infectious Diseases (NIAID) highlights this issue in their article released on the 25th anniversary of National Black HIV/AIDS Awareness Day, Working Together to End HIV in Black Communities - https://lnkd.in/gATws8rn   At Sedia, we're committed to advancing access to care and improving the lives of those affected by HIV. Asante® Rapid Recency enables detection of recent HIV infection at the point of care, helping to identify populations with high HIV transmission. The NIAID article highlights community engagement, education, and empowerment as critical elements for achieving public health goals. Rapid Recency can contribute to these efforts by: 1️⃣ Recency testing complements standard HIV diagnostic testing, providing information for better understanding of where new infections occur which can further support HIV prevention, treatment, and care efforts. 2️⃣ HIV recency testing data can inform targeted, population-level HIV prevention and testing interventions.   By leveraging technology and innovation in the Asante Rapid Recency test, Sedia is working to help end the HIV epidemic, including for disproportionately affected individuals and groups.   To learn more about how Sedia and Asante Rapid Recency are contributing to the efforts to end AIDS, reach out to us or visit our website - https://lnkd.in/dca2szd5. Together we make a difference, let's unite in the fight against HIV/AIDS! #hivawareness #hivaids #NIAID

We are excited to share this impactful collaboration from our subsidiary, Floragenex.

Today, on the 35th World AIDS Day, we take pause to reflect on the vital importance of continuing the fight against HIV. At Sedia Biosciences, we are proud of our ongoing contributions in the struggle against the HIV/AIDS epidemic. The attached article highlights several challenges we continue to face on the journey toward HIV/AIDS elimination, including proposed cuts to HIV funding and the delay in the reauthorization of PEPFAR. On this World AIDS Day, recognizing our global health partners and acknowledging all of those affected by HIV, Sedia again will ‘remember and commit’ to our work focused on controlling the spread of this virus, helping the world to reach the goal of a future free of HIV/AIDS. https://lnkd.in/gUKq7KMF ##WorldAIDSDay #GlobalHealth #InnovationThatMatters

We are excited to share a recent study that utilized our Asanté® HIV-1 Rapid Recency® Assay, during their research.    The study, titled "Recent HIV infections among newly diagnosed individuals living with HIV in rural Lesotho: Secondary data from the VIBRA cluster-randomized trial," provides insights into the HIV epidemic in Lesotho.    The researchers conducted a door-to-door HIV testing campaign in villages in two rural districts in Northern Lesotho. Participants were evaluated for recency of infection using our Asanté® HIV-1 Rapid Recency® Assay, paired with HIV viral load testing when indicated. The study aimed to determine the proportion of recent HIV infections and identify risk factors associated with these infections.    The study found that 7% of those who were newly diagnosed with HIV in the study had acquired the infection within the previous 6 months. These findings highlighted the ongoing transmission risk for HIV in rural communities in Lesotho and the pressing need for effective prevention measures in this setting.    The Asanté® Rapid Recency® Assay played a pivotal role in accurately identifying recent HIV infections in rural communities in Lesotho, enabling researchers to both gather data and inform prevention strategies. Sedia is proud that our product contributed to this important study that sought to better understand HIV transmission patterns in order to adequately tackle the HIV epidemic in Lesotho and beyond.    To read the full study, click here: https://lnkd.in/ezZ2CqmT   Stay tuned for more updates on how Asanté® HIV-1 Rapid Recency® Assay and Sedia Biosciences continue to empower researchers and healthcare professionals in the fight against HIV.